Devyser HBOC for NGS

Pinpoint gene mutations with a recognised connection to the development of breast and ovarian cancers.

Detect mutations in genes with a recognised connection to the development of breast and ovarian cancers
Can be used as a follow-up after negative BRCA testing, or combined with Devyser BRCA for analysis of 14 genes in total
End-to-end CE-IVD solution including NGS library preparation and a customised data interpretation software
Targeted sequencing with high uniformity reduces sequencing costs by maximising sample capacity on every NGS flowcell
User friendly workflow with 45 mins hands-on time and a total laboratory process time of five hours from DNA to sequencing

Genes included in the Devyser HBOC CE-IVD gene panel

ATM	PTEN	BARD1
RAD51C	RAD51D	BRIP1
CDH1	STK11	CHEK2
TP53	NBN	PALB2
BRCA1*	BRCA2*	*Through combined protocol with Devyser BRCA

Designed for genetic testing in hereditary breast and ovarian cancers

The Devyser HBOC gene panel has been developed with an integrative approach towards the varying literature and expert recommendations for follow-up after negative BRCA testing. It can also be employed as a first-line protocol simultaneously with BRCA1 and BRCA2, extending the screening by an additional 12 genes. Its purpose is to pinpoint mutations in genes with a recognised connection to the development of breast and ovarian cancers.

Quick and easy implementation

With ready-to-use reagents, less than 45 minutes hands-on time and customised data interpretation software, it is a good match for laboratories of any size. The targeted sequencing approach combined with uniform coverage of target regions maximises the output of relevant sequencing data in every run.

Identify variants to guide testing of at-risk relatives

Genetic testing of these genes may help guide treatment and management decisions. Identification of a disease-causing variant would also guide testing of at-risk relatives. This test is specifically designed for heritable germline mutations.